Comparative Pharmacology
Head-to-head clinical analysis: FUNDUSCEIN 25 versus PYLORI CHEK BREATH TEST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUNDUSCEIN 25 versus PYLORI CHEK BREATH TEST.
FUNDUSCEIN-25 vs PYLORI-CHEK BREATH TEST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorescein sodium absorbs blue light (465–490 nm) and emits yellow-green fluorescence (520–530 nm), allowing visualization of retinal and choroidal vasculature. It binds to serum proteins and leaks from abnormal blood vessels, highlighting areas of neovascularization or edema.
Urea labeled with 13C is hydrolyzed by urease enzyme produced by Helicobacter pylori, producing 13CO2 which is exhaled and detected in breath.
0.5 mL of FUNDUSCEIN-25 (25 mg/mL) administered intravenously as a single bolus injection over 5-10 seconds.
Adults: 75 mg of 13C-urea dissolved in 75 mL of water, administered orally as a single dose. Breath samples collected at baseline and 30 minutes post-dose.
None Documented
None Documented
Terminal elimination half-life is approximately 26 minutes in adults (range 20–30 minutes). Clinical context: Rapid clearance allows repeated injections within 30–60 minutes if needed.
The elimination half-life of 13C-urea is approximately 0.5–1 hour in patients with normal renal function, reflecting rapid renal clearance. In severe renal impairment, half-life may be prolonged up to 7–10 hours.
Primarily renal elimination of unchanged fluorescein and its glucuronide conjugate (80% within 24 hours). Biliary/fecal excretion accounts for <5%.
13C-urea is excreted renally as intact urea (approximately 85%) and as 13CO2 in breath (approximately 15%). Fecal elimination is negligible. In renal impairment, breath 13CO2 excretion may increase as renal clearance decreases.
Category C
Category C
Diagnostic Agent
Diagnostic Agent